American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

Patients with type 1 diabetes comorbid with metabolic dysfunction-associated steatotic liver disease had a low prevalence of advanced liver fibrosis.

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...